Incretin Atlas › Trials › IMPACT
IMPACT
Pemvidutide · MASH F2–F3
Design
- Molecule(s)
- Pemvidutide
- Population
- MASH F2–F3
- Official title
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
- Sponsor
- Altimmune, Inc.
- Phase
- Phase 2
- Registry status
- completed · 2023-07 → 2025-11
- Participants
- 212
- Duration
- 24 weeks
- Registry
- NCT05989711
Outcomes in the indication
IMPACT Pemvidutide · MASH F2–F3 · 24 weeks · n = 212 abstract
MASH resolution without worsening of fibrosis +38 / +32 percentage points vs placebo at 24 weeks (1.2 / 1.8 mg); fibrosis improvement +5 / +8, not significant. At 48 weeks (no biopsy): liver fat −37.1 / −46.5 percentage points vs placebo.
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| MASH resolution without worsening of fibrosis 1.2 mg week 24 | +58.0 | +20.0 | +38.0 (+21.0 to +56.0) percentage points | abstract |
| MASH resolution without worsening of fibrosis 1.8 mg week 24 | +52.0 | +20.0 | +32.0 (+19.0 to +46.0) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of MASH 1.2 mg week 24 | +33.0 | +28.0 | +5.0 (−13.0 to +22.0) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of MASH 1.8 mg week 24 | +36.0 | +28.0 | +8.0 (−6.0 to +22.0) percentage points | abstract |
Verbatim quotes (4)
- MASH resolution without worsening of fibrosis
MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1.2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0.0001), and 45 (52%) of 85 patients in the 1.8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0.0001)
- MASH resolution without worsening of fibrosis
MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1.2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0.0001), and 45 (52%) of 85 patients in the 1.8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0.0001)
- Fibrosis improvement (≥1 stage) without worsening of MASH
Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1.2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0.59), and 30 (36%) of 85 patients in the 1.8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0.27)
- Fibrosis improvement (≥1 stage) without worsening of MASH
Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1.2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0.59), and 30 (36%) of 85 patients in the 1.8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0.27)
Primary sources
- Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, Sheikh MY, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025;406(10520):2644-2655. PMID: 41237796.
- Noureddin M, Alkhouri N, Loomba R, Chalasani N, Sheikh MY, Tomah S, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet Gastroenterol Hepatol. 2026. PMID: 43014327.
- Altimmune, Inc.. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT). ClinicalTrials.gov identifier NCT05989711. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05989711
How to cite this page
Medical Adviser's Group. Incretin Atlas: IMPACT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/impact/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.